Societal CDMO (NASDAQ: SCTL) will release its financial results for Q1 2022 on May 11, 2022, after market close. The company specializes in complex formulation and manufacturing challenges in small molecule therapeutics. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and operational highlights. Interested parties can access the call via phone or through the company’s website. An archived version will be available for 30 days post-event.
Societal CDMO (SCTL) has secured a task order agreement exceeding $400,000 from the National Cancer Institute’s DCTD for the manufacture and packaging of ammonium tetrathiomolibdate (ATTM) capsules. This project will involve developing a scalable process for cGMP production of 100 mg ATTM capsules, including an engineering batch and a larger cGMP batch with a 36-month stability study. ATTM is believed to enhance the effectiveness of platinum-based antitumor agents. CEO David Enloe emphasized the company's commitment to supporting cancer research through this collaboration.
Societal CDMO (NASDAQ: SCTL) has announced the hiring of new employees to fill various roles, along with the approval of inducement stock option grants totaling 107,540 shares. These options, granted under NASDAQ's inducement grant exception, have an exercise price aligned with the stock closing price on March 31, 2022, and will vest over four years. The company specializes in contract development and manufacturing, focusing on small molecules, and operates state-of-the-art facilities in Gainesville, GA, and San Diego, CA.